CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

fluticasone furoate/vilanterol

Last Updated: June 17, 2020
Result type: Reports
Project Number: SR0524-000
Product Line: Reimbursement Review

Generic Name: fluticasone furoate/vilanterol

Brand Name: Breo Ellipta

Manufacturer: GlaxoSmithKline Inc.

Therapeutic Area: COPD

Indications: COPD

Submission Type: Resubmission

Project Status: Withdrawn

Biosimilar: No

Key Milestones2

Call for patient input postedMay 31, 2017
Patient group input closedJuly 20, 2017

- Patient input submission received

Patient input summary sent for review to patient input groupsJuly 25, 2017
Patient group comments on input summary closedAugust 01, 2017

- Patient input summary feedback received

Submission receivedJune 28, 2017
Submission acceptedJuly 13, 2017
Review initiatedJuly 14, 2017
Draft CADTH review report(s) sent to sponsorSeptember 28, 2017
Comments from sponsor on draft CADTH review report(s) receivedOctober 10, 2017
Redaction requests from sponsor on draft CADTH review report(s) receivedOctober 17, 2017
CADTH review team's comments on draft CADTH review report(s) sent to sponsorNovember 03, 2017

- Voluntarily withdrawn by the manufacturer on 2017-Nov-09